CHICAGO — Cemiplimab demonstrated considerable antitumor activity among patients with metastatic cutaneous squamous cell carcinoma, according to results of the EMPOWER-CSCC-1 trial presented at ASCO Annual Meeting.
Researchers concluded the trial results strongly support the recent FDA approval of cemiplimab (Libtayo; Regeneron, Sanofi Genzyme), a human monoclonal antibody that targets PD-1.
Alexander Guminski, MD, a medical oncologist from Sydney, Australia, and one of the investigators on the trial, spoke with HemOnc Today about the trial results and their potential clinical implications.
“This trial establishes a new standard for the treatment of patients with metastatic cutaneous squamous cell carcinoma, which is an important and often underrepresented and underrecognized disease,” Guminski told HemOnc Today. – by Mark Leiser
Reference: Guminski AD, et al. Abstract 9526. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Disclosure: Guminski reports advisory board roles with Merck KGaA, Pfizer, Regeneron, Sanofi and Sun Pharma.